Alan D. Robertson

TL;DR: This study has defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110β isoform in regulating the formation and stability of integrin αIIbβ3 adhesion bonds, necessary for shear activation of platelets, as an important new target for antithrombotic therapy.

TL;DR: Novel 2-aminothieno[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors are described, which were designed by combining structural elements of distinct low affinity hits generated from fragment-based and in silico screening exercises in concert with structural information from X-ray protein crystallography.

TL;DR: The receptor specificity of the drug and its actions on trigeminal‐evoked plasma protein extravasation into the dura mater of the anaesthetized guinea‐pig is described and the inability of 5‐ HT1B/1D agonists to achieve the same maximum as the endogenous agonist 5‐HT is explained by the additional presence of5‐HT2A receptors.

TL;DR: In this article, the present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3; W is a group of formula W, where R is hydrogen or C1-4 alkyl, X is -O-, -S-, -NH-, or -CH2-, Y is oxygen or sulphur and the chiral centre in formula W is in its (S) or (R) form or is a mixture thereof in any proportions.

TL;DR: Utilizing the pharmacophore model in conjunction with the physicochemical constraints of molecular size and log DpH7.4 led to the discovery of 311C90 (6), a new selective 5-HT1D agonist with good oral absorption and potential use in the treatment of migraine.